mitoxantrone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics; anthraquinone derivatives 1821 65271-80-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitoxantrone
  • mitoxantrone hydrochloride
  • dihydroxyanthraquinone
  • mitoxanthrone
  • mitozantrone
  • nimitoxantron
  • mitoxantrone dihydrochloride
  • mitoxantrone HCl
An anthracenedione-derived antineoplastic agent.
  • Molecular weight: 444.49
  • Formula: C22H28N4O6
  • CLOGP: 2.24
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 8
  • TPSA: 163.18
  • ALOGS: -2.78
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 7.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.78 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.25 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1987 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 304.10 26.17 165 5211 97502 50502246
Acute myeloid leukaemia 207.91 26.17 73 5303 15001 50584747
Myelodysplastic syndrome 159.10 26.17 60 5316 15072 50584676
Pancytopenia 127.51 26.17 90 5286 83940 50515808
Second primary malignancy 116.78 26.17 39 5337 6875 50592873
Sepsis 112.54 26.17 101 5275 132824 50466924
Acute promyelocytic leukaemia 103.66 26.17 23 5353 861 50598887
Neutropenia 103.29 26.17 101 5275 147864 50451884
Thrombocytopenia 83.20 26.17 84 5292 127589 50472159
Leukaemia recurrent 80.40 26.17 20 5356 1234 50598514
Haemophagocytic lymphohistiocytosis 75.63 26.17 30 5346 8603 50591145
Progressive multifocal leukoencephalopathy 70.66 26.17 31 5345 11426 50588322
Bone marrow failure 70.19 26.17 41 5335 27583 50572165
Acute myeloid leukaemia recurrent 68.64 26.17 18 5358 1372 50598376
Bronchopulmonary aspergillosis 65.17 26.17 26 5350 7566 50592182
Febrile bone marrow aplasia 59.03 26.17 23 5353 6288 50593460
Chronic hepatitis 56.89 26.17 14 5362 826 50598922
Congestive cardiomyopathy 51.22 26.17 20 5356 5498 50594250
Lower respiratory tract infection fungal 47.70 26.17 10 5366 285 50599463
Product use in unapproved indication 47.58 26.17 60 5316 115759 50483989
Mucormycosis 45.89 26.17 15 5361 2468 50597280
Cardiac failure 43.99 26.17 47 5329 75993 50523755
Haematotoxicity 41.16 26.17 19 5357 7876 50591872
Acute lymphocytic leukaemia recurrent 40.87 26.17 13 5363 1962 50597786
Streptococcal bacteraemia 40.37 26.17 12 5364 1446 50598302
Abdominal wall wound 40.10 26.17 7 5369 72 50599676
Chloroma 39.05 26.17 8 5368 203 50599545
Graft versus host disease 39.04 26.17 17 5359 6149 50593599
Bone marrow infiltration 37.85 26.17 9 5367 459 50599289
Hypogammaglobulinaemia 37.02 26.17 16 5360 5683 50594065
Myeloblast percentage decreased 36.56 26.17 6 5370 41 50599707
Refractory cytopenia with multilineage dysplasia 35.71 26.17 7 5369 141 50599607
Multiple organ dysfunction syndrome 34.32 26.17 34 5342 50303 50549445
Aspergillus infection 34.26 26.17 16 5360 6805 50592943
Hepatitis E 33.53 26.17 10 5366 1219 50598529
Arthralgia 30.61 26.17 5 5371 438697 50161051
Stem cell transplant 30.52 26.17 10 5366 1658 50598090
Stenotrophomonas infection 30.51 26.17 10 5366 1659 50598089
Bacterial sepsis 29.71 26.17 12 5364 3600 50596148
Respiratory failure 29.40 26.17 42 5334 91139 50508609
Clostridium bacteraemia 28.16 26.17 6 5370 185 50599563
Colitis 28.08 26.17 27 5349 38502 50561246
Chronic myeloid leukaemia 28.00 26.17 10 5366 2146 50597602
Venoocclusive liver disease 27.80 26.17 12 5364 4249 50595499
Leukopenia 27.72 26.17 35 5341 67493 50532255
Differentiation syndrome 27.23 26.17 8 5368 925 50598823
Cardiomyopathy 26.63 26.17 18 5358 15568 50584180
Aplastic anaemia 26.59 26.17 14 5362 7689 50592059
Streptococcal sepsis 26.33 26.17 9 5367 1698 50598050
Neoplasm progression 26.25 26.17 23 5353 29134 50570614

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 356.91 22.00 253 6468 111987 29455819
Myelodysplastic syndrome 166.27 22.00 81 6640 17713 29550093
Acute myeloid leukaemia 141.85 22.00 71 6650 16442 29551364
Neutropenia 108.39 22.00 141 6580 131570 29436236
Septic shock 100.15 22.00 95 6626 62465 29505341
Bone marrow failure 82.28 22.00 60 6661 27389 29540417
Bronchopulmonary aspergillosis 80.05 22.00 44 6677 12300 29555506
Mucormycosis 75.06 22.00 32 6689 5126 29562680
Fungal infection 73.17 22.00 43 6678 13642 29554164
Second primary malignancy 60.99 22.00 30 6691 6675 29561131
Minimal residual disease 53.61 22.00 13 6708 330 29567476
Bacteraemia 51.89 22.00 37 6684 16286 29551520
Ameloblastoma 51.52 22.00 10 6711 84 29567722
Aspiration bone marrow abnormal 49.50 22.00 10 6711 105 29567701
Leukaemia recurrent 46.18 22.00 16 6705 1461 29566345
Multiple organ dysfunction syndrome 44.75 22.00 63 6658 63053 29504753
Hypertensive hydrocephalus 41.56 22.00 8 6713 64 29567742
Acute lymphocytic leukaemia recurrent 41.26 22.00 17 6704 2499 29565307
Neoplasm progression 39.09 22.00 33 6688 18579 29549227
Haematopoietic neoplasm 37.19 22.00 7 6714 49 29567757
Thrombocytopenia 36.80 22.00 89 6632 134734 29433072
Mucosal inflammation 35.96 22.00 40 6681 31555 29536251
Abscess fungal 35.19 22.00 8 6713 152 29567654
Neoplasm recurrence 34.61 22.00 14 6707 1963 29565843
Cytogenetic abnormality 34.07 22.00 11 6710 808 29566998
Clostridium bacteraemia 33.87 22.00 7 6714 83 29567723
Aspergillus infection 33.66 22.00 24 6697 10557 29557249
Cystitis haemorrhagic 33.43 22.00 18 6703 4824 29562982
Pancytopenia 33.11 22.00 64 6657 83104 29484702
Pneumonia fungal 33.11 22.00 19 6702 5758 29562048
Cardiotoxicity 30.98 22.00 17 6704 4727 29563079
Gallbladder adenocarcinoma 30.02 22.00 5 6716 15 29567791
Product use in unapproved indication 29.98 22.00 63 6658 86812 29480994
Venoocclusive liver disease 29.95 22.00 19 6702 6898 29560908
Sepsis 29.55 22.00 85 6636 142597 29425209
Neutropenic colitis 28.73 22.00 13 6708 2398 29565408
Refractory anaemia with an excess of blasts 27.97 22.00 8 6713 389 29567417
Disease progression 27.80 22.00 59 6662 81857 29485949
Respiratory tract infection fungal 27.73 22.00 9 6712 672 29567134
Klebsiella infection 26.49 22.00 18 6703 7331 29560475
Genotoxicity 26.44 22.00 5 6716 36 29567770
Klebsiella sepsis 26.33 22.00 11 6710 1673 29566133
Enamel anomaly 26.15 22.00 6 6715 119 29567687
Progressive multifocal leukoencephalopathy 25.96 22.00 19 6702 8700 29559106
Colitis 24.85 22.00 33 6688 31215 29536591
Hyperammonaemic encephalopathy 24.57 22.00 11 6710 1979 29565827
Osteonecrosis 24.41 22.00 22 6699 13497 29554309
Fungaemia 23.60 22.00 11 6710 2170 29565636
Differentiation syndrome 23.41 22.00 9 6712 1104 29566702
Large granular lymphocytosis 23.41 22.00 6 6715 192 29567614
Cholangitis infective 22.24 22.00 6 6715 235 29567571

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 537.19 20.30 351 10287 187306 64300788
Acute myeloid leukaemia 328.61 20.30 135 10503 27328 64460766
Myelodysplastic syndrome 314.51 20.30 131 10507 27448 64460646
Neutropenia 179.97 20.30 209 10429 239415 64248679
Second primary malignancy 169.35 20.30 67 10571 12270 64475824
Bone marrow failure 149.43 20.30 95 10543 47857 64440237
Leukaemia recurrent 115.24 20.30 34 10604 2560 64485534
Sepsis 114.60 20.30 164 10474 230177 64257917
Bronchopulmonary aspergillosis 102.75 20.30 54 10584 19031 64469063
Septic shock 101.55 20.30 105 10533 105332 64382762
Thrombocytopenia 99.25 20.30 151 10487 223650 64264444
Pancytopenia 97.41 20.30 119 10519 143190 64344904
Acute promyelocytic leukaemia 92.59 20.30 25 10613 1363 64486731
Mucormycosis 87.39 20.30 36 10602 7305 64480789
Progressive multifocal leukoencephalopathy 77.15 20.30 44 10594 18188 64469906
Acute lymphocytic leukaemia recurrent 73.74 20.30 27 10611 3999 64484095
Fungal infection 71.41 20.30 53 10585 34198 64453896
Product use in unapproved indication 69.65 20.30 113 10525 176505 64311589
Multiple organ dysfunction syndrome 68.50 20.30 84 10554 101329 64386765
Bacteraemia 68.44 20.30 47 10591 26864 64461230
Acute myeloid leukaemia recurrent 63.61 20.30 22 10616 2762 64485332
Venoocclusive liver disease 61.59 20.30 31 10607 9984 64478110
Clostridium bacteraemia 59.92 20.30 13 10625 277 64487817
Haemophagocytic lymphohistiocytosis 55.07 20.30 35 10603 17574 64470520
Aspergillus infection 54.86 20.30 34 10604 16345 64471749
Ameloblastoma 54.71 20.30 10 10628 84 64488010
Neoplasm recurrence 53.72 20.30 21 10617 3718 64484376
Cytogenetic abnormality 52.05 20.30 15 10623 1039 64487055
Refractory anaemia with an excess of blasts 50.67 20.30 14 10624 832 64487262
Lower respiratory tract infection fungal 50.52 20.30 14 10624 841 64487253
Chronic hepatitis 49.31 20.30 15 10623 1253 64486841
Febrile bone marrow aplasia 47.17 20.30 27 10611 11228 64476866
Neoplasm progression 47.15 20.30 45 10593 40919 64447175
Differentiation syndrome 46.03 20.30 16 10622 2038 64486056
Fungaemia 43.15 20.30 18 10620 3767 64484327
Respiratory failure 42.90 20.30 87 10551 161096 64326998
Klebsiella sepsis 42.16 20.30 16 10622 2616 64485478
Drug resistance 41.24 20.30 39 10599 35063 64453031
Stenotrophomonas infection 39.72 20.30 16 10622 3064 64485030
Colitis 38.62 20.30 48 10590 58626 64429468
Stem cell transplant 37.83 20.30 16 10622 3465 64484629
Aplastic anaemia 37.01 20.30 25 10613 13895 64474199
Neutropenic colitis 36.70 20.30 17 10621 4564 64483530
Fatigue 36.51 20.30 42 10596 748688 63739406
Haematotoxicity 36.31 20.30 24 10614 12872 64475222
Abdominal wall wound 36.11 20.30 7 10631 83 64488011
Cystitis haemorrhagic 35.81 20.30 20 10618 7936 64480158
Haematopoietic neoplasm 35.81 20.30 7 10631 87 64488007
Hyperammonaemic encephalopathy 35.47 20.30 16 10622 4042 64484052
Candida infection 35.18 20.30 34 10604 31385 64456709
Malignant neoplasm progression 34.99 20.30 65 10573 112806 64375288
Graft versus host disease 34.81 20.30 24 10614 13789 64474305
Respiratory tract infection fungal 34.42 20.30 11 10627 1081 64487013
Stomatococcal infection 34.16 20.30 8 10630 243 64487851
Myeloblast percentage decreased 33.92 20.30 6 10632 41 64488053
Refractory cytopenia with multilineage dysplasia 33.55 20.30 8 10630 263 64487831
Hypogammaglobulinaemia 33.53 20.30 21 10617 10278 64477816
Cardiomyopathy 33.33 20.30 30 10608 25326 64462768
Bone marrow infiltration 33.28 20.30 9 10629 493 64487601
Hypertensive hydrocephalus 33.06 20.30 5 10633 10 64488084
Enterococcal infection 32.40 20.30 23 10615 13843 64474251
Cardiac failure 32.34 20.30 69 10569 132304 64355790
Pyrexia 31.70 20.30 178 10460 558466 63929628
Mucosal inflammation 31.64 20.30 45 10593 62539 64425555
Nausea 31.33 20.30 51 10587 785749 63702345
Arthralgia 31.33 20.30 17 10621 442243 64045851
Acute lymphocytic leukaemia 31.26 20.30 15 10623 4356 64483738
Hepatic failure 31.25 20.30 42 10596 55352 64432742
Diffuse large B-cell lymphoma recurrent 29.40 20.30 13 10625 3133 64484961
Pain 29.22 20.30 29 10609 553482 63934612
Abscess fungal 28.85 20.30 7 10631 248 64487846
Osteonecrosis 28.73 20.30 29 10609 28200 64459894
Acute febrile neutrophilic dermatosis 28.70 20.30 13 10625 3316 64484778
Pneumonia fungal 28.64 20.30 18 10620 8859 64479235
Drug hypersensitivity 28.57 20.30 3 10635 237812 64250282
Chronic myeloid leukaemia 28.53 20.30 13 10625 3361 64484733
Hepatitis B 28.29 20.30 17 10621 7728 64480366
Fall 28.12 20.30 17 10621 416809 64071285
Chronic lymphocytic leukaemia recurrent 27.70 20.30 8 10630 558 64487536
Lymphopenia 27.29 20.30 27 10611 25630 64462464
Pseudomonas infection 27.21 20.30 23 10615 17860 64470234
Disseminated intravascular coagulation 27.17 20.30 30 10608 32318 64455776
Aspiration bone marrow abnormal 27.09 20.30 6 10632 141 64487953
Disease progression 27.03 20.30 67 10571 141613 64346481
Pruritus 26.91 20.30 9 10629 312391 64175703
Pulmonary haemorrhage 26.67 20.30 20 10618 13089 64475005
Klebsiella infection 26.44 20.30 20 10618 13261 64474833
Cardiotoxicity 26.24 20.30 18 10620 10256 64477838
Leukopenia 26.14 20.30 54 10584 101188 64386906
Chloroma 25.97 20.30 8 10630 697 64487397
Hepatitis E 25.84 20.30 11 10627 2420 64485674
Dizziness 25.75 20.30 20 10618 430143 64057951
Blood culture positive 25.50 20.30 16 10622 7852 64480242
Escherichia bacteraemia 25.46 20.30 14 10624 5389 64482705
Minimal residual disease 25.43 20.30 7 10631 410 64487684
Staphylococcal infection 24.96 20.30 36 10602 50642 64437452
Chromosome analysis abnormal 24.58 20.30 6 10632 218 64487876
Pain in extremity 23.97 20.30 10 10628 303075 64185019
Portal hypertension 23.63 20.30 14 10624 6205 64481889
Streptococcal bacteraemia 23.39 20.30 11 10627 3056 64485038
Pseudomonal sepsis 23.27 20.30 13 10625 5159 64482935
Acute myelomonocytic leukaemia 23.04 20.30 6 10632 284 64487810
Streptococcal sepsis 22.73 20.30 10 10628 2382 64485712
Encephalopathy 22.27 20.30 37 10601 58782 64429312
Nasopharyngitis 22.25 20.30 3 10635 196070 64292024
Cerebral fungal infection 22.11 20.30 6 10632 333 64487761
Metastasis 22.11 20.30 13 10625 5682 64482412
Large granular lymphocytosis 21.94 20.30 6 10632 343 64487751
Leukaemic infiltration 21.70 20.30 5 10633 141 64487953
Chronic myelomonocytic leukaemia 21.33 20.30 7 10631 748 64487346
Bacterial sepsis 21.29 20.30 14 10624 7443 64480651
Pneumonia 21.10 20.30 161 10477 559415 63928679
Acute graft versus host disease 21.06 20.30 15 10623 9069 64479025
Primary hypogonadism 20.75 20.30 5 10633 172 64487922
Parametritis 20.59 20.30 3 10635 4 64488090
Retinal infiltrates 20.51 20.30 4 10634 49 64488045
Cholangitis infective 20.31 20.30 6 10632 453 64487641

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
FDA MoA N0000000176 Topoisomerase Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D059005 Topoisomerase II Inhibitors
FDA EPC N0000175609 Topoisomerase Inhibitor
CHEBI has role CHEBI:23240 chromophores
CHEBI has role CHEBI:37958 dyes
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378
Metastatic Prostate Carcinoma indication
Follicular non-Hodgkin's lymphoma off-label use 308121000
Metastatic Breast Carcinoma off-label use
Progressive Diffuse Large B-Cell Lymphoma off-label use
Mycosis contraindication 3218000 DOID:1564
Viral disease contraindication 34014006 DOID:934
Chronic heart failure contraindication 48447003
Hepatic failure contraindication 59927004
Acute infectious disease contraindication 63171007
Leukopenia contraindication 84828003 DOID:615
Left heart failure contraindication 85232009
Bacterial infectious disease contraindication 87628006
Radiation oncology AND/OR radiotherapy contraindication 108290001
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.37 acidic
pKa2 10.7 acidic
pKa3 9.13 Basic
pKa4 8.52 Basic
pKa5 4.01 Basic
pKa6 1.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR IC90 5.96 WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.84 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.31 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.73 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.74 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.11 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.05 DRUG MATRIX
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter IC50 6.29 WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter Kact 5.16 WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.27 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.90 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.69 DRUG MATRIX
Serine/threonine-protein kinase pim-1 Kinase IC50 7.29 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.36 CHEMBL
DNA-(apurinic or apyrimidinic site) lyase Enzyme IC50 5.70 CHEMBL
Tyrosine-protein kinase BTK Kinase IC50 6 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase IC50 5.52 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.13 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 6.72 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.28 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.22 CHEMBL
DNA-3-methyladenine glycosylase Enzyme IC50 5.60 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.53 DRUG MATRIX
TAR DNA-binding protein 43 Unclassified IC50 5 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.75 DRUG MATRIX
Integrase Enzyme IC50 5.42 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase AC50 5.02 CHEMBL

External reference:

IDSource
4019842 VUID
N0000147929 NUI
D02166 KEGG_DRUG
70476-82-3 SECONDARY_CAS_RN
4019527 VANDF
4019842 VANDF
C0026259 UMLSCUI
CHEBI:50729 CHEBI
MIX PDB_CHEM_ID
CHEMBL58 ChEMBL_ID
CHEMBL1417019 ChEMBL_ID
CHEMBL1200827 ChEMBL_ID
D008942 MESH_DESCRIPTOR_UI
DB01204 DRUGBANK_ID
7242 IUPHAR_LIGAND_ID
4922 INN_ID
BZ114NVM5P UNII
4212 PUBCHEM_CID
203129 RXNORM
5124 MMSL
81184 MMSL
d00306 MMSL
002676 NDDF
004828 NDDF
108791001 SNOMEDCT_US
386913001 SNOMEDCT_US
412249002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4680 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4685 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4686 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 63323-132 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 15 sections